Compare Abeona Therapeutics Inc (ABEO) vs Burlington Stores Inc (BURL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Burlington Stores Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Burlington Stores Inc trades at $314.01 (market cap $19.90B). The key difference: Burlington Stores Inc is far larger — about 53.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Burlington Stores Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BURL | |
|---|---|---|
Market Cap | $373.32M | $19.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $347.82 |
52-Week Low | $4.17 | $242.43 |
Enterprise Value | $228.22M | $25.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Burlington Stores (BURL) trades at $312.36, showing modest daily decline of -0.26% but maintaining strong fundamental performance with consistent earnings beats. The stock exhibits bearish technical signals despite positive analyst sentiment, with 94% buy ratings and a $364.40 consensus price target. Recent Q1 2026 results exceeded expectations with $2.01 EPS versus $1.80 expected, marking the 14th consecutive quarter of double-digit earnings growth.
BURL presents a compelling growth story with expanding margins and store expansion plans, though technical indicators suggest near-term caution. The stock's premium valuation (P/E 32.14) reflects growth expectations, while competitive pressures and consumer spending sensitivity remain key risks. Upside potential exists toward analyst targets if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
